Table 1 Patient distribution according to clinicopathological and radiologic factors
No. of patients | Total = 121 |
|---|---|
Clinical factor | |
Sex (%) | |
 Male | 56 (46.3) |
 Female | 65 (53.7) |
Age, median (IQR) | 58 (52–68) |
Smoking (%) | |
 Never | 82 (67.8) |
 Ever | 39 (32.2) |
Surgical procedure (%) | |
 Sublobar resection | 8 (6.6) |
 Lobectomy | 113 (93.4) |
Neoadjuvant or adjuvant treatment (%) | |
 No | 92 (76) |
 Yes | 29 (24.0) |
CT factor | |
CT morphology (%) | |
 Nodular type | 91 (75.2) |
 Consolidative type | 30 (24.8) |
Solidity (%) | |
 Solid | 63 (52.1) |
 Part-solid | 58 (47.9) |
 Well-defined heterogenous GGO (%) | 15 (12.4) |
 Lobulated margin (%) | 47 (38.8) |
 Spiculated margin (%) | 38 (31.4) |
 CT air-bronchogram (%) | 70 (57.9) |
 CT angiogram sign (%) | 25 (20.7) |
Pathologic factor | |
Surgical bronchial margin (%) | |
 > 1 cm | 98 (81) |
 ≤ 1 cm | 9 (7.4) |
NA | 14 (11.6) |
T stage (%) | 1.6 (0.5) |
1A/B | 53 (43.8) |
2A/B | 67 (55.4) |
3 | 1 (0.8) |
N stage (%) | |
 0 | 106 (87.6) |
 1 | 5 (4.1) |
 2 | 10 (8.3) |
 No. of LNs dissected, median (IQR) | 15 (9–21) |
TNM stage (%) | |
 I | 82 (67.8) |
 II | 24 (19.8) |
 III | 15 (12.4) |
Tumor differentiation (%) | |
 Well | 89 (73.6) |
 Moderate | 25 (20.7) |
 Poor | 7 (5.8) |
Aerogenous spread (%) | |
 No | 52 (43.0) |
 Yes | 62 (51.2) |
 NA | 7 (5.8) |
Mucin (%) | |
 No | 39 (32.2) |
 Yes | 71 (58.7) |
 NA | 11 (9.1) |
STAS (%) | |
 No | 31 (25.6) |
 Yes | 79 (65.3) |
 NA | 11 (9.1) |
EGFR mutation (%) | |
 No | 11 (9.1) |
 Yes | 21 (17.3) |
 NA | 89 (73.6) |
Prognosis | |
OS event, yes (median follow-up period 81.4 [IQR, 41.8–109.5 months]) | 31 (25.6) |
DFS event, yes (median follow-up period 59.8 [IQR, 24.6–104.6 months]) | 35 (28.9) |